1t4j: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Obesity and type II diabetes are closely linked metabolic syndromes that, afflict >100 million people worldwide. Although protein tyrosine, phosphatase 1B (PTP1B) has emerged as a promising target for the treatment, of both syndromes, the discovery of pharmaceutically acceptable inhibitors, that bind at the active site remains a substantial challenge. Here we, describe the discovery of an allosteric site in PTP1B. Crystal structures, of PTP1B in complex with allosteric inhibitors reveal a novel site located, approximately 20 A from the catalytic site. We show that allosteric, inhibitors prevent formation of the active form of the enzyme by blocking, mobility of the catalytic loop, thereby exploiting a general mechanism, used by tyrosine phosphatases. Notably, these inhibitors exhibit, selectivity for PTP1B and enhance insulin signaling in cells. Allosteric, inhibition is a promising strategy for targeting PTP1B and constitutes a, mechanism that may be applicable to other tyrosine phosphatases.
Obesity and type II diabetes are closely linked metabolic syndromes that afflict >100 million people worldwide. Although protein tyrosine phosphatase 1B (PTP1B) has emerged as a promising target for the treatment of both syndromes, the discovery of pharmaceutically acceptable inhibitors that bind at the active site remains a substantial challenge. Here we describe the discovery of an allosteric site in PTP1B. Crystal structures of PTP1B in complex with allosteric inhibitors reveal a novel site located approximately 20 A from the catalytic site. We show that allosteric inhibitors prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases. Notably, these inhibitors exhibit selectivity for PTP1B and enhance insulin signaling in cells. Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases.


==Disease==
==Disease==
Line 17: Line 17:
[[Category: Protein-tyrosine-phosphatase]]
[[Category: Protein-tyrosine-phosphatase]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Barr, K.J.]]
[[Category: Barr, K J.]]
[[Category: Fahr, B.J.]]
[[Category: Fahr, B J.]]
[[Category: Hansen, S.K.]]
[[Category: Hansen, S K.]]
[[Category: Kung, J.]]
[[Category: Kung, J.]]
[[Category: McDowell, R.S.]]
[[Category: McDowell, R S.]]
[[Category: Randal, M.]]
[[Category: Randal, M.]]
[[Category: Shen, W.]]
[[Category: Shen, W.]]
Line 31: Line 31:
[[Category: allosteric inhibition protein tyrosine phosphatase 1b]]
[[Category: allosteric inhibition protein tyrosine phosphatase 1b]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:55:15 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:09:56 2008''